The Los Angeles Post
U.S. World Business Lifestyle
Today: March 18, 2025
Today: March 18, 2025

Biohaven surges as genetic disease drug meets main study goal

Biohaven Pharmaceutical Holding Company logo is displayed on screen on floor of NYSE in New York
September 23, 2024
Reuters - Reuters

By Christy Santhosh

(Reuters) -Biohaven's drug for a genetic disease that affects the nervous system met the main study goal, sending its shares up more than 12% as the trial data allayed investor worries following a setback last year.

The company said on Monday it would submit a marketing application to the U.S. Food and Drug Administration (FDA) based on the trial and was prepared for a potential launch in 2025.

In July 2023, the health regulator declined to review the company's marketing application based on a late-stage study of the drug, troriluzole, from 2022, as it had failed to meet the main goal.

"We believe the vast majority of investors had written troriluzole off completely" said Piper Sandler analyst Christopher Raymond.

With a launch next year, Raymond sees U.S. revenue from the drug touching $250 million by 2030.

Troriluzole is part of Biohaven's non-migraine drugs spun off into a new company in 2022, after Pfizer acquired the migraine assets in an $11.6 billion deal.

In the trial, the drug showed 50% to 70% slowing of disease progression in patients with Spinocerebellar Ataxia (SCA) after three years of treatment, the company said on Monday.

SCA is caused by the degeneration of cells in brain and spinal cord and can lead to uncoordinated movement and muscle wasting.

It affects about 15,000 people in the U.S., according to company estimates, and has no approved treatments in the country.

(Reporting by Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Sriraj Kalluvila)

Related Articles

Germany's Merck in advanced talks to acquire US biotech firm SpringWorks Novo Nordisk defends next-gen obesity drug CagriSema, details new trial US FDA approves Vertex's non-opioid painkiller Surprise finding sheds light on what causes Huntington's disease, a devastating fatal brain disorder
Share This

Popular

Asia|Business|Political|World

Hong Kong leader opposes 'coercion and bullying' by foreign governments

Hong Kong leader opposes 'coercion and bullying' by foreign governments
Business|Environment|Finance|Political|US

BlackRock, Vanguard, State Street ask court to dismiss US antitrust lawsuit

BlackRock, Vanguard, State Street ask court to dismiss US antitrust lawsuit
Asia|Business|Economy|Finance|Stock Markets

Hong Kong stocks and kiwi rise on China outlook

Hong Kong stocks and kiwi rise on China outlook
Business|Political|US

Getting paid not to work: Federal probationary workers are being reinstated but put on paid leave

Getting paid not to work: Federal probationary workers are being reinstated but put on paid leave

Health

Europe|Health|Political|World

King Charles praying that visit to see Pope will go ahead

King Charles praying that visit to see Pope will go ahead
Crime|Health|Political|US

Texas woman arrested for providing โ€˜illegal abortions,โ€™ Texas attorney general says

Texas woman arrested for providing โ€˜illegal abortions,โ€™ Texas attorney general says
Environment|Europe|Health|Political|Travel|World

Britainโ€™s King Charles and Queen Camilla to visit Pope Francis next month

Britainโ€™s King Charles and Queen Camilla to visit Pope Francis next month
Health|MidEast|Political|US

Homeland Security says professor deported to Lebanon with US visa supported Hezbollah leader

Homeland Security says professor deported to Lebanon with US visa supported Hezbollah leader